Search Results Showing 2 of 2 search results for: Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of CC-95775 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma Status Recruiting Condition Lymphoma, Non-Hodgkin Phase Phase 1 INTERVENTION Drug: CC-95775 Eligibility Ages Eligible for Study : Sexes Eligible for Study : All Accepts Healthy Volunteers : Result 1 of 2 Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies Status Completed Condition Acute Myeloid Leukemia, Acute Myelogenous Leukemia, Myelodysplast... Phase Phase 1 INTERVENTION Drug: FT-1101, Drug: Azacitidine Eligibility Ages Eligible for Study : Sexes Eligible for Study : All Accepts Healthy Volunteers : Result 2 of 2